The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Participant New York Heart Association (NYHA) functional class
Timeframe: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Left ventricular outflow tract (LVOT) gradient results at rest, Valsalva and post-exercise (if available)
Timeframe: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Left ventricular ejection fraction (LVEF) percentage
Timeframe: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Maximum left ventricular wall thickness
Timeframe: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant age
Timeframe: Baseline
Participant gender
Timeframe: Baseline
Participant race
Timeframe: Baseline
Participant ethnicity
Timeframe: Baseline
Participant insurance coverage
Timeframe: Baseline
Participant Body Mass Index
Timeframe: Baseline
Participant blood pressure
Timeframe: Baseline
Participant heart rate
Timeframe: Baseline
Participant genotype
Timeframe: Baseline
Participant family history
Timeframe: Baseline
Participant New York Functional Class classification
Timeframe: Baseline
Participant echocardiogram measurements
Timeframe: Baseline
Participant comorbidities
Timeframe: Baseline
Participant hypertrophic cardiomyopathy (HCM) treatment history
Timeframe: Baseline
Mavacamten index dose prescribed
Timeframe: Baseline
Participant obstructive hypertrophic cardiomyopathy (oHCM) symptoms (syncope, shortness of breath, fatigue, exercise intolerance, palpitations)
Timeframe: Baseline